New research offers fresh hope to patients with colorectal cancer, as advances in liquid biomarker technologies are ...

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure ...

Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...

Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of ...

Scientists have developed Spudcell, an advanced synthetic cell capable of adapting to its environment and learning survival skills, marking a breakthrough in synthetic biology.

Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an ...

The Food and Drug Administration authorized Gain Therapeutics' investigational new drug application for a Parkinson's disease treatment, clearing the way for the biotechnology company to launch a ...